Navigation Links
FM Series Flowmeters - Oxygen Power Take Off

ProductsFM Series Flowmeters - Oxygen Power Take Off
Company Western Medica
Item FM Series Flowmeters - Oxygen Power Take Off
Features 
  • Oxygen, Medical Air and Carbon Dioxide Flowmeters available
  • Chrome Plated Brass Body
  • Full line of inlet connections available
  • Optional power take-off units provide 50 psi additional outlet pressure
  • Double units for multipatient use from one wall outlet
  • Polycarbonate inner and outer tubes provide greater accuracy and durability
    • Description FM Series Oxygen Flowmeters with Power Take Off

    Options:
  • For security chain, add suffix S to model number. Example: FM107S.
  • For Canadian Color-Code, add suffix C to model number. Example: FM104C.
  • For Double Flowmeters with Power Take-Off, add PT to model number. Example: FMPT409.
    • Info Western Medica
    Customer Service: (800) 783-7890
    Web site: http://www.westernmedica.com/

    Related medicine products :

    1. Series 20000 Legacy
    2. Series 24 Watt Sealed CO2 OEM Lasers
    3. M/MK Series
    4. EA/EKA Series
    5. EHS Series
    6. MLS-Series Top-Loading Autoclaves
    7. Blood Coagulation Analyzer CG Series
    8. Cytomics FC 500 Series
    9. Series 400 Aggregometers
    10. Series 500 Aggregometers
    11. Series 490 Low Cost Automatic Optical Aggregometers
    ...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
    ...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
    ...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
    ...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
    Medicine Products:
    (Date:9/5/2008)...an be controlled, but you need to know what trigge...5 (HealthDay News) -- If you are one of the 36 mil... there is nowhere in the United States that is fre... report shows. , Allergies don,t only happen in...ns as well. In the fall, the most challenging citi...
    (Date:9/5/2008)...ANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthrosurfa...eloper of less-invasive joint,resurfacing systems,...U.S.,FDA to begin its pivotal investigation for it... stated that "there are no outstanding safety,conc...tion., Arthrosurface has been evaluating the safe...
    (Date:9/5/2008)...e National Institute of Diabetes and Digestive and...titutes of Health (NIH), announces awards to eight...e studies of urologic chronic pelvic pain disorder...state. The total research investment for the five-...n. , "The launch of this novel research effort i...
    (Date:9/5/2008)...DLOTHIAN, Va., Sept. 5 /PRNewswire/ -- On Saturday...featured on the Oxygen Network show Today,s,Family... highlighted as a,leading medical device company t...h effective nebulizers and compressors that delive... vision is to improve the lives of those affected ...
    Breaking Medicine News(10 mins):Health News:No Place Safe From Allergies 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2
    ...y said it had got the go-ahead from Nigerian autho...e lives of 11 children in the northern Kano state ...(Nigeria's drug agency), the federal ministry of h...r guardians of the children before the clinical te...
    ...simple form of exercise that can keep blood pressu...ms or mental health in check - walking. So says M...n expert on obesity, who insists that all people ...eep healthy. "Getting out there and taking a wal...
    ...ome smokers have genetic predisposition to develop...he research from Wake Forest University School of ...some people increases their chances of developing ...cco. "The genetic variant we studied seemed harml...
    ...ting a tattoo done of their lover's initials due t...good news - researchers have discovered a techniqu... or removed as per the wearer's choice. The new m... where particles are suspended in a biodegradable ...
    Other Medicine News:Health News:Walking Really is the Best Way to Keep Healthy 2Health News:Genetic Variation in Some Smokers Increases Chances of Developing COPD 2
    (Date:9/4/2008)...ort demonstrates potent antiviral activity and fav...e -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-FirstC...X ), a biopharmaceutical company engaged,in the di... of human viral,and other infectious diseases, tod...ncept study evaluating IDX899, a non-nucleoside re...
    (Date:9/3/2008)... China, Sept. 3 /- Simcere,...facturer and supplier of,branded generic pharmaceu...r biotech product Endu (also known as Endostar) in...e IV clinical study., At the request of the SFDA,...rther validate the safety and therapeutic efficacy...
    (Date:9/3/2008)...BURG, Md., Sept. 3 /- Panacea Pharmac.... Patent Number 7,413,737 covering,antibodies agai...(HAAH), a,proprietary human cancer biomarker and t... in collaboration with the Massachusetts Institute...rldwide rights to this patent,for development of h...
    (Date:9/3/2008)...to be Evaluated in Repeat-Dosing Study in Subjects...FirstCall/ -- Sangamo,BioSciences, Inc. (Nasdaq: ...2 clinical trial (SB-509-801) to evaluate its drug...enerative motor-neuron disease for which there,are...s drug, SB-509, is an injectable formulation of a ...
    Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5GNC Schedules Conference Call and Webcast to Report Third Quarter 2007 Financial Results 5274 1Michael J Fox Foundation Commits Up to 242 Million for PD Drug Development Under Target Validation 2008 5269 1Michael J Fox Foundation Commits Up to 242 Million for PD Drug Development Under Target Validation 2008 5269 2Report shows less than half of kids in California are being read to daily 5266 1Report shows less than half of kids in California are being read to daily 5266 2Report shows less than half of kids in California are being read to daily 5266 3Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 1Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 2Elbit Medical Imaging Ltd Announces Results of Its Annual General Meeting 1656 3
    ...ainst Cancer-Causing Virus,Types 16 & 18 That ...ion Levels, CHICAGO, June 05, 2007 /PRNewswire/ --...he first of a three-dose regimen, 100,percent of w...ine,(GSK) cervical cancer candidate vaccine had an...r-causing human papillomavirus,types, 16 and 18. T...
    ... these data reassuring", PHILADELPHIA, June 05, 20...today that findings from an interim analysis,of RE... and,Regulation of glycemia in Diabetes), a prospe...rmine cardiovascular outcomes in more,than 4,400 p...e to,the overall cardiovascular safety profile of ...
    Other Medicine Technology:Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 2Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 3Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 4Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides,Sustained Immune Response in 100 Percent of Women up to 55 Years of,Age 5Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5